CD33 is widely used as a marker for tumor infiltrating myeloid cells (Choi et al., 2020; Toor et al., 2021), so we collected FFPEs from 28 consecutive pairs of BC patients and performed IHC for CD74 and CD33, respectively. Here, CD74 is linked to breast cancer.